Lantheus Holdings Inc (LNTH) Director Brian A. Markison Sells 5,000 Shares

Share on StockTwits

Lantheus Holdings Inc (NASDAQ:LNTH) Director Brian A. Markison sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $24.75, for a total value of $123,750.00. Following the completion of the transaction, the director now directly owns 67,467 shares in the company, valued at $1,669,808.25. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of NASDAQ LNTH traded down $1.45 during midday trading on Friday, hitting $24.25. 602,262 shares of the stock traded hands, compared to its average volume of 322,160. The stock has a market capitalization of $991.08 million, a price-to-earnings ratio of 25.80, a PEG ratio of 1.92 and a beta of 1.52. The company has a debt-to-equity ratio of 3.16, a current ratio of 4.57 and a quick ratio of 3.82. Lantheus Holdings Inc has a one year low of $12.59 and a one year high of $26.40.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03. The firm had revenue of $86.51 million for the quarter, compared to analysts’ expectations of $86.80 million. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. Equities research analysts anticipate that Lantheus Holdings Inc will post 1.11 EPS for the current year.

Several equities analysts recently issued reports on the company. Zacks Investment Research cut Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. BidaskClub cut Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 18th. TheStreet raised Lantheus from a “c+” rating to a “b” rating in a research report on Monday, March 4th. Finally, ValuEngine raised Lantheus from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Lantheus has a consensus rating of “Buy” and an average target price of $23.33.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LNTH. PNC Financial Services Group Inc. lifted its holdings in shares of Lantheus by 51.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 575 shares during the period. Tyers Asset Management LLC purchased a new stake in shares of Lantheus in the 1st quarter worth $39,000. Riverhead Capital Management LLC purchased a new stake in shares of Lantheus in the 1st quarter worth $44,000. Financial Gravity Companies Inc. purchased a new stake in shares of Lantheus in the 4th quarter worth $45,000. Finally, C M Bidwell & Associates Ltd. purchased a new stake in shares of Lantheus in the 1st quarter worth $45,000. 92.98% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Lantheus Holdings Inc (LNTH) Director Brian A. Markison Sells 5,000 Shares” was originally published by Equities Focus and is the property of of Equities Focus. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.equitiesfocus.com/2019/05/17/lantheus-holdings-inc-lnth-director-brian-a-markison-sells-5000-shares.html.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Featured Article: Trading Options- What is a Strangle?

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.